Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Sep 24, 2025; 16(9): 109730
Published online Sep 24, 2025. doi: 10.5306/wjco.v16.i9.109730
Published online Sep 24, 2025. doi: 10.5306/wjco.v16.i9.109730
Overview of Yttrium-90 radioembolization for advanced hepatocellular carcinoma: Current status and future perspectives
Zong-Yang Li, Cheng Xie, Hong-Qiao Cai, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Author contributions: Cai HQ designed the overall concept and outline of the manuscript; Li ZY contributed to the discussion and design of the manuscript; Xie X contributed to the writing, and editing the manuscript, illustrations, and review of literature.
Conflict-of-interest statement: The authors have claimed no conflicts of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hong-Qiao Cai, MD, PhD, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun 130021, Jilin Province, China. hongqiaocai@jlu.edu.cn
Received: May 20, 2025
Revised: May 27, 2025
Accepted: July 10, 2025
Published online: September 24, 2025
Processing time: 126 Days and 21.7 Hours
Revised: May 27, 2025
Accepted: July 10, 2025
Published online: September 24, 2025
Processing time: 126 Days and 21.7 Hours
Core Tip
Core Tip: Radioembolization with yttrium-90 microspheres represents a pivotal locoregional treatment option for patients with advanced hepatocellular carcinoma (HCC), especially those with portal vein tumor thrombosis or limited tolerance to systemic therapies. Landmark trials confirm its favorable safety profile and potential for tumor downstaging. Emerging strategies such as personalized dosimetry and combination with immunotherapy are poised to enhance efficacy. Radioembolization continues to evolve as a core component of multimodal therapy in advanced HCC management.